213252-19-8

KRP-297 is a PPARα and PPARγ agonist potentially for the research of type 2 diabetes and dyslipidemia. KRP-297 restores reduced lipid oxidation, and inhibits of enhanced lipogenesis and triglyceride accumulation in the liver.

KRP 927 is a thiazolidinedione dual agonist of PPARα and PPARγ (EC50s = 149 and 83 nM, respectively, in transactivation assays).1 It decreases hyperglycemia and hyperinsulinemia in ob/ob mice in a dose-dependent manner. KRP 927 (10 or 30 mg/kg) reduces serum total cholesterol and triglyceride levels in hamsters.

1.Doebber, T.W., Kelly, L.J., Zhou, G., et al.MK-0767, a novel dual PPARα/γ agonist, displays robust antihyperglycemic and hypolipidemic activitiesBiochem. Biophys. Res. Commun.318(2)323-328(2004)